Amyotrophic lateral sclerosis (ALS) is a devastating neurodegenerative disease which causes progressive and eventually fatal loss of motor function. Here we describe genetic and pathological characterisation of brain tissue banked from 19 ALS patients over nearly 20 years at the Department of Anatomy and the Centre for Brain Research, University of Auckland, New Zealand. We screened for mutations in SOD1, TARDBP, FUS, and C9ORF72 genes, and for neuropathology caused by phosphorylated TDP-43, dipeptide repeats and ubiquilin. We identified two cases with C9ORF72 repeat expansions. Both harboured phosphorylated TDP-43 and dipeptide repeat inclusions. We show that dipeptide repeat inclusions can incorporate or occur independently of ubiquilin. We also identified one case with a UBQLN2 mutation, which showed phosphorylated TDP-43 and characteristic ubiquilin protein inclusions. This is the first study of ALS genetics in New Zealand, adding New Zealand to the growing list of countries in which C9ORF72 repeat expansion and UBQLN2 mutations are detected in ALS cases.
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Introduction
The Neurological Foundation of New Zealand Human Brain Bank at the Centre for Brain Research, University of Auckland, was established in 1994 to collect brain and associated tissue from donors with neurological diseases including amyotrophic lateral sclerosis (ALS). With a growing number of genetic causes of ALS identified by researchers internationally we sought to examine the genetics and neuropathology of our ALS brain bank cases as a subset of ALS patients in New Zealand.
The genetic basis for approximately 18% of ALS cases is accounted for, with the GGGGCC expansion mutation in intron 1 of C9ORF72 alone comprising ~10% of all ALS. Exonic mutations in SOD1, FUS and TARDBP, along with rarer ALS genes (UBQLN2, OPTN, TBK1, SQSTM1 etc.) found predominantly in FALS cases, comprise the remaining cases (Renton, et al., 2014) . Despite the diverse genetic and environmental factors, ~97% of all ALS cases show a common neuropathology characterised by the deposition of phosphorylated TDP-43 aggregates (Neumann, et al., 2006) . The presence of additional protein aggregates can indicate specific genetic causes of ALS. For example, in addition to TDP-43 pathology, C9ORF72 mutations also cause dipeptide repeat (DPR) protein aggregates in the cerebellum and hippocampus (Ash, et al., 2013 . Conversely, FUS and SOD1 mutant cases do not show TDP-43 proteinopathy, but rather deposition of the mutant proteins themselves (Mackenzie, et al., 2007 , Vance, et al., 2009 . Neuropathological analyses can therefore be used in conjunction with genetics to fully characterise ALS cases.
Here we examine genetic and pathological features of ALS in New Zealand using banked brain tissue. We identify C9ORF72 and UBQLN2 as genetic causes of ALS in New Zealand and confirm that cases with these mutations display characteristic neuropathological lesions. These findings will allow us to best utilise and share our existing bequests as well as establishing a platform for larger genetic and neuropathological studies of ALS in New Zealand. 
Materials and Methods
Subjects, ethics and human tissue banking
DNA extraction from fixed and fresh brain tissue
One hundred mg fixed-frozen tissue and/or 300 mg fresh-frozen tissue from lateral cerebellum and/or rostral superior frontal gyrus was used. DNA was extracted from fresh tissue (n=10 cases) using standard phenol-chloroform-isoamyl alcohol extraction and DNA clean-up performed using Microclean (Microzone). DNA was extracted from fixed-frozen tissue (n=17 cases) using the QiaAmp FFPE Tissue Kit (Qiagen).
Sanger sequencing and repeat-primed PCR
All coding exons and flanking sequence of SOD1 (Refseq NM_00454), exon 6 of TARDBP (Refseq NM_007375), and exons 6, 14 and 15 of FUS (Refseq NM_001170937) were amplified using standard PCR and directly sequenced with Big-Dye Terminator v1.1 on an ABI3130 DNA analyser (Applied Biosystems). Samples were screened for the C9ORF72 GGGGCC repeat expansion mutation using repeat-primed PCR (DeJesus-Hernandez, et al., 2011 ) and fragment analysis conducted on an ABI3130 DNA analyser and peaks visualized using Genemapper 4.0.
Neuropathology
Fifty micron free-floating sections were taken from fixed-frozen sensory-motor cortex blocks or hippocampus blocks and immunohistochemistry performed using antibodies listed in Supplementary material (Waldvogel, et al., 2008 , Waldvogel, et al., 2006 . Wide-field images were acquired using a Nikon Eclipse Ni microscope (20x magnification, 0.13 NA) and confocal images sourced using a Zeiss LSM 710 inverted confocal microscope (63x magnification, 1.4 NA, Z-step 0.34 µm) with ZEN 2012 software (Carl Zeiss). Maximum intensity Z-projections and orthogonal projections were generated using ImageJ software (http://imagej.nih.gov/ij/).
Results
Demographics of ALS in New Zealand
Controls
(n=4)
ALS cases All cases (n=19)
C9ORF72-negative (n=17)
C9ORF72-positive (n=2) Male: female (n) 50% (2):50% (2) 47% (9): 53% (10) 53% (9) 19.1 ± 6.9, 9-23.5 20.8 ± 17.1, 3-69* *Excluding MN2 for which this information was unavailable.
A detailed clinical description of cases harbouring mutations can be found in Supplementary Material.
Genetic analysis of banked ALS cases
One of our cases had tested positive for UBQLN2 p.T487I mutation in life (patient IV:18 in ). Another case tested negative for C9ORF72, SOD1, TARDBP and FUS during life. All other cases were screened for these genes using DNA extracted from brain. Freshfrozen brain DNA, available for 10 cases, gave a high rate of sequencing success. Fixed-frozen brain DNA gave only ~50% viable sequence. We identified one fALS patient (MN18) with C9ORF72 repeat expansion (Fig. 1A) , however DNA was not available from other affected family members to test segregation.
Neuropathology of banked ALS cases
We next conducted immunohistochemistry on all 19 cases. All showed classical phosphorylated TDP-43 deposits in the motor cortex (Fig. 1B) , thus ruling out SOD1 and FUS gene mutations (Mackenzie, et al., 2007 , Vance, et al., 2009 . No phosphorylated TDP-43 inclusions were seen in controls, nor when phospho-TDP-43 primary antibody was omitted. We also screened using an antibody to the poly-glycine-proline DPR (Ash, et al., 2013) . The C9ORF72-positive case (MN18) showed hallmark deposition of DPR aggregates in the dentate gyrus and cornus ammonis (CA) regions of the hippocampus (Fig. 1C a-d) . A second fALS case (MN2) also showed DPRs. For this case, C9ORF72
repeat-primed PCR of fixed-frozen brain DNA had been unsuccessful, however follow-up with the M A N U S C R I P T A C C E P T E D ACCEPTED MANUSCRIPT 5 patient's family revealed an affected offspring had tested positive. No DPR staining was seen in control hippocampus, any C9ORF72-negative ALS cases, nor when primary antibody was omitted.
Finally, by screening using an antibody to ubiquilin 2 we confirmed that the case with UBQLN2 p.T487I mutation (MN17) showed deposition of ubiquilin in the hippocampus, particularly in the parahippocampal region and molecular layer of the dentate gyrus but not in the granular layer (Fig.   1D a-d) . In cases with C9ORF72 mutation, ubiquilin-positive inclusions were observed in the CA regions and in both the granular and molecular layers (Fig. 1D e-h ). Using double-label confocal microscopy we found that DPRs in the granular layer could be found alone, or decorating a core of ubiquilin (Fig. 1E) . No ubiquilin staining was seen when primary antibody was omitted.
Discussion
This study is the first to explore the genetics and neuropathology of ALS in New Zealand. With a total population of only 4.5 million, and an estimated current cohort of 300 people living with ALS, ALS research in New Zealand to date has been on a small scale. However after 20 years of banking brain tissue, and with growing national and international support for ALS research, the time was ripe for characterisation of our bank as a foundation for growth of a New Zealand ALS research programme.
Using combined genetic and neuropathological screening we identified two C9ORF72 mutation carriers and a UBQLN2 p.T487I carrier. The C9ORF72-positive cases showed abundant deposition of DPRs in the hippocampus. Although TDP-43 proteinopathy correlates better with regional neurodegeneration (Mackenzie, et al., 2013) , DPRs are pathognomonic for C9ORF72-linked disease thus staining for DPRs can augment genetic screening. Before the discovery of DPRs it was found that C9ORF72-positive cases could also be distinguished by the presence of p62 and ubiquilin protein pathology in the hippocampus and cerebellum (Al-Sarraj, et al., 2011 , Brettschneider, et al., 2012 . Although TDP-43 inclusions can be ubiquilin-modified (Deng, et al., 2011) they are rare in hippocampus before late stage (Brettschneider, et al., 2013) therefore hippocampal ubiquilin pathology is considered a surrogate for DPRs (Brettschneider, et al., 2012 , Mann, et al., 2013 . We showed using double-label immunofluorescence that polyGP DPRs are ubiquilin-modified in the dentate granular layer, while ubiquilin inclusions in the molecular layer were DPR-negative.
Ubiquilin inclusions have also been seen in the hippocampus and spinal cord in ALS caused by
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6 UBQLN2 gene mutation (Deng, et al., 2011 , and indeed we detected hippocampal ubiquilin inclusions in case MN17 with UBQLN2 p.T487I mutation.
While this study was essential for characterising our banked tissue for future use, we screened only a small number of patients who may not necessarily be representative of the wider New Zealand ALS cohort. For instance, 5 of our 19 cases (26%) had a family history of ALS while most studies report that 5-10% of ALS is familial. Their over-representation in our brain bank may suggest that familial ALS patients are more highly motivated to bequeath tissue for research. For this reason, the inclusion in our cohort of a case with a rare UBQLN2 mutation should not be over interpreted. The frequency of C9ORF72 mutation in our cohort, 2 of 5 familial cases (40%), agrees with the expected frequency of 37.6% for European populations (Majounie, et al., 2012) .
This study profiles ALS genetics and pathology in a small New Zealand cohort. Moving forward, we seek to press for inclusion of New Zealand ALS patients in international cohort studies and clinical trials.
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Patient MN18
The patient was a European (Australian) female with onset at age 47, presenting with lower limb weakness. Concomitant FTD was not suspected. The patient died at the age of 53. The patient's mother was diagnosed with early Alzheimer's at age 60, and a maternal aunt was diagnosed with unspecified dementia. A maternal uncle was diagnosed with MND but was not known to have dementia.
Patient MN17
The patient was a European female, presenting with ALS of spinal onset at the age of 58 with distal upper limb weakness, progressing to severe weakness in all limbs and anarthria within 3 years. FTD was suspected clinically, developing fairly late, with confirmed executive dysfunction. The patient died at the age of 61. The patient's mother, sister, and brother died of ALS aged 48, 38, and 43 years, respectively. The family history of ALS was extensive. At the time of her death, 9 of 22 of the patient's family had died of ALS. No male-to-male transmission was seen, consistent with X-linked disease. This patient and kindred have been described in detail previously, during the patient's life . 
